Four’s Company? WHO Not Yet Recommending Quadrivalent Flu Vaccines
Executive Summary
While FDA has approved MedImmune’s quadrivalent version of its seasonal influenza vaccine FluMist and GlaxoSmithKline has submitted an application for approval for one, the World Health Organization is not yet ready to recommend replacing the standard trivalent vaccines.
You may also be interested in...
Quadrivalent FluMist Clears FDA But Won’t Be On The Market Until 2013
MedImmune does not expect improved sales of the intranasal vaccine based on the enhanced formulation.
Janssen’s Sirturo Needs Minor Tweaks To Confirmatory Trial, FDA Panel Says
Gathering more data to assuage concerns about possibly lower efficacy in black patients will be key to converting the accelerated approval to full approval for the tuberculosis drug, FDA’s Anti-Infective Drugs Advisory Committee concludes.
Ranbaxy’s Atorvastatin Recall: Will Glass Shards Nick FDA’s Reputation?
Less than a year after signing a consent decree to resolve compliance problems, the company is forced to stop manufacturing its generic version of the best-selling cholesterol drug. For FDA, the issue poses a public relations challenge since it touches on several areas where the agency has recently been criticized – generic drug quality, manufacturing oversight and drug shortages.